Recent studies have provided direct evidence for genetic variegation in subclones for various cancer types. However, little is known about subclonal evolutionary processes according to treatment and subsequent relapse in multiple myeloma (MM). This issue was addressed in a cohort of 24 MM patients treated either with conventional chemotherapy or with the proteasome inhibitor, bortezomib. As MM is a highly heterogeneous disease associated with a large number of chromosomal abnormalities, a subset of secondary genetic events that seem to reflect progression, 1q21 gain, NF-kB-activating mutations, RB1 and TP53 deletions, was examined. By using high-resolution single-nucleotide polymorphism arrays, subclones were identified with nonlinear complex evolutionary histories. Such reordering of the spectrum of genetic lesions, identified in a third of MM patients during therapy, is likely to reflect the selection of genetically distinct subclones, not initially competitive against the dominant population but which survived chemotherapy, thrived and acquired new anomalies. In addition, the emergence of minor subclones at relapse appeared to be significantly associated with bortezomib treatment. These data support the idea that new strategies for future clinical trials in MM should combine targeted therapy and subpopulations' control to eradicate all myeloma subclones in order to obtain long-term remission.
INTRODUCTION
Multiple myeloma (MM) is a highly heterogeneous disease at presentation, which impacts response intensities among homogeneously treated patients. Considerable progress has, however, been achieved in the treatment of MM in the past decade, with survival improvement in newly diagnosed MM patients after the introduction of novel effective drugs, such as the immunomodulatory compound thalidomide, its analog, lenalidomide and the proteasome inhibitor, bortezomib. [1] [2] [3] [4] [5] Yet, almost all MM patients still relapse after treatment, which emphasizes a need for new insights into relapse mechanisms. Among current hypotheses, that of a composite disease with competing subclones at diagnosis and the emergence at relapse of initially minor populations is being increasingly acknowledged and supported. 6 In this study, the question investigated was whether such dynamics of subclonal diversification and evolution could contribute to relapse in MM. In newly diagnosed MM patients, there is a large diversity of clonal evolution stages 7 as well as contrasted numbers of chromosomal abnormalities. 8, 9 This study therefore focused on the investigation of copy number changes and/or loss of heterozygosity (LOH) involving secondary genetic events associated with MM relapse such as 1q21 gain, NF-kB-activating mutations, RB1 and TP53 deletions, through the comparison of paired MM diagnosis and relapse samples.
MATERIALS AND METHODS

Patients and samples
Paired bone marrow (BM) samples collected at both diagnosis and relapse/ progression from 24 patients initially treated in the Intergroupe Francophone du Myé lome (IFM) centers either with bortezomib and dexamethasone (Vel/D) or with conventional chemotherapy (VAD: vincristine, adriamycin and dexamethasone) were included in this study (Supplementary Table 1 ). They were 17 males and 7 females, with a median age of 59 years (range . The median duration of remission was 24.5 months (range . Peripheral blood (PB) was also collected at relapse for 17 out of the 24 patients.
The requirements of the Declaration of Helsinki were fulfilled for all cases.
Sample preparation BM and PB specimens (3 ml) were obtained during standard diagnostic and follow-up procedures in IFM centers, collected on EDTA and shipped overnight to the Hematology Laboratory at University Hospital in Nantes (France). Plasma cell purification was performed as previously described. 10 The mean CD138 þ plasma cell purity was 98.1% (median 98.5; range 85-100) and 98.4% (median 99.0; range 92-100) for diagnosis and relapse samples, respectively. Aliquots of purified malignant plasma cells (500 000 cells) were frozen at À 80 1C in lysis buffer (RLT þ Qiagen, Valencia, CA, USA). 1 
Nucleic acid purification
After thawing, DNA and RNA were extracted from one aliquot using the AllPrep DNA/RNA MiniKit (Qiagen) in accordance with the manufacturers' instructions. DNA and RNA quality and quantity were assessed using the Nanodrop Spectrophotometer (NanoDrop Technologies Inc., Wilmington, DE, USA). RNA integrity was assessed using Agilent 2100 Bioanalyzer (Agilent, Palo Alto, CA, USA). For germline studies, genomic DNA was extracted from buffy coats prepared from 1 ml of PB samples using GE Healthcare Nucleon BACC Genomic DNA Extraction kits (GE Healthcare Bio-Sciences Corp., Piscataway, NJ, USA).
Genomic analysis
DNA copy number and LOH analyses were performed on 24 diagnosisrelapse-paired BM MM samples and 17 PB/germline samples. DNA (500 ng) was processed and hybridized to Affymetrix Genome-Wide Human SNP Array 6.0 according to the manufacturer's instructions (Affymetrix, Santa Clara, CA, USA), with the exception of one diagnostic MM sample (#24) hybridized onto Affymetrix Human SNP 500K array.
Affymetrix CEL files were analyzed using Affymetrix Genotyping Console software v4.0 (GTC 4.0) for initial quality control, followed by use of the Affymetrix Birdseed algorithm v2.0 to generate single-nucleotide polymorphism (SNP) genotype calls. Genotyping using the Birdseed algorithm was performed using at least 44 arrays in each analysis. Call rates were between 97.3 and 99.74 with a mean call rate of 98.96. For MM sample #24, SNP genotype calls were generated using the BRLMM algorithm in GTC 4.0 (SNP call: 98.65 for NSP and 98.01 for STY). All samples passed the Affymetrix recommended contrast QC and SNP call rates threshold.
Copy number and LOH determinations were performed on CEL files using both Partek Genomic Suite software, version 6.5, build 6.10.0212 (Partek Inc., St Louis, MO, USA; http://www.partek.com/) and Affymetrix (GTC 4.0) using software with default parameters. Baseline data were generated on paired blood DNA or International HapMap samples. The profiles were visualized with Partek Genomic Suite or Affymetrix Chromosome Analysis Suite software (ChAS v1.0.1) according to the initial analysis. Sample copy number heatmap displays were obtained from CEL files through use of the freely available dChip software (http://www.dchip.org) adapted to a 64-bit operating system environment. 11 
Accession codes
Minimum information about a microarray experiment-compliant data have been deposited at Gene Expression Omnibus with accession number GSE37459.
Clustering analysis
Clustering analysis was performed using dChip software based on the Pearson's correlation coefficient of log 2 ratio copy number data.
Segmentation analysis
The detection and determination of three types of genomic events, respectively, gains, losses and copy neutral-LOH (CN-LOH) was performed using the BRLMM-P þ algorithm in GTC 4.0. To locate segments with copy number or LOH changes in CNCHP data files, Affymetrix ChAS software was used. Segmentation results were smoothed and filtered to use only segments 4200 kb for gain or loss, and 44000 kb for CN-LOH. For detection of biallelic deletions the cutoff used was 450 kb.
To systematically identify genomic lesions including copy number abnormalities, LOH and minor clones present at diagnosis and at relapse, a sequential visual analysis was performed for each sample. First, copy number abnormalities (CNAs) and CN-LOH segments identified according to ChAS filters were manually curated compared with germline DNA or Figure 1 . Hierarchical clustering of diagnosis and relapse MM established by SNP array data. Each case is represented by two columns for diagnosis and relapse (R). dChip median-smoothed log 2 ratio Affymetrix SNP 6.0 copy number data are arranged from 1p(tel) to Xq(tel) from top to bottom. Unsupervised hierarchical clustering of copy number data showed coclustering of all paired diagnostic and relapse samples examined. Deletions are in blue and amplifications in red. Chr., chromosome.
pooled unpaired germline samples to exclude inherited copy number variants and segments arising from experimental artifact (for example, interbatch effects). Second, segment results were compared with log 2 ratio, total copy number state and allele difference results. In case of discrepancies between these parameters, smoothing window size and segment filters were changed. Third, abnormalities present in minor clones undetected by segmentation analysis were identified using total copy number and allele-specific copy number estimates obtained using Partek Genomic Suite analysis as well as allele difference and log 2 ratio obtained by GTC 4.0 analysis to manually define emerging segments. The Genomic Segmentation algorithm of Partek Genomic Suite for Genome-Wide Human SNP Array 6.0 was used to validate segmentation analysis results.
DNA gains and losses arising from B-cell receptor gene rearrangements at 2p11.2 (IGK@), 14q32.33 (IGH@) and 22q11.22 (IGL@) were excluded from the analysis.
Detection of minor populations and assessment of relative frequencies of subclones A visual reference was constructed for each lesion type (gain, loss or CN-LOH) based on spiking increased amount of tumoral DNA harboring the lesion in matched germline DNA (Supplementary Figures 1-3 ). This scale, based on total copy number, allele ratio and allele-specific copy number determinations, was used to estimate the proportion of MM clones
Diagnosis
Relapse harboring a specific lesion within myeloma cells lacking this abnormality. The detection threshold of a minor subclone was established at 20%.
Breakpoint analyses
Based on decreased microarray signal intensities, primers flanking the predicted deletions were designed using Primer3
. PCR was performed on relapse samples using 100 ng genomic DNA in accordance with the manufacturers' instructions (Advantage 2 PCR Kit, Clontech, Mountain View, CA, USA) with the following thermal program: 1-min initial denaturation at 95 1C; 35 cycles of 30 s at 95 1C and 3 min at 681 followed by a 3-min final extension step at 68 1C. Genomic deletion breakpoints were defined by direct sequencing of PCR products. PCR genotyping across breakpoints was then performed on DNA from BM diagnosis samples either with initial primers (MM_#11) or primers designed by sequencing of the deletion breakpoints (MM_#42: P42 5_S 5 0 -CAGTCCC TGAACTTCACTCCTCACG-3 0 , P42 3_3). DNA from a PB sample of patient MM_#42 at relapse was also tested.
Gene set enrichment analysis MM samples for which 50 ng of total RNA from diagnosis and relapse samples was available (11 cases) were processed according to NuGEN manufacturer's instruction (NuGEN, San Carlos, CA, USA) before labeling and hybridization onto Affymetrix Human Exon1.0 chip according to the manufacturer's instructions (Affymetrix). For each gene of interest, Spearman's correlation coefficient (rho) was computed between the . Nonlinear subclonal evolution with new acquisitions at relapse in patient no. 11. (a) Relapse clone originating from minor subclone at diagnosis with bifurcation and diversification. Rows (dots) display the copy number (CN) defined as the median-smoothed intensity with a window of five markers of diagnosis (blue) and relapse (red), bottom rows display allele ratio (AR) for each SNP. 1q21.3-q44 gain at diagnosis; CN at 3 indicates one predominant subclone. At relapse: 1q gain LOH; CN at 4 and AR with a two allele track combination (homozygous SNPs cluster at ratios around À 1 and 1) indicate that the most likely subclone that gave rise to relapse had 1q gain LOH undetectable at diagnosis. Acquisition of del13q14-q22 and biallelic deletion of TRAF3 at relapse. Dashed circle indicates that the frequency of this subclone is too low (o20%) to be detected. Secondary genetic lesions with changes between diagnostic and relapse are indicated in red. (b) Genomic pattern of TRAF3 rearrangements acquired at relapse. Top left, genomic map showing position and log 2 ratio copy number of array probes as individual vertical line (orange for diagnosis and blue for relapse) and region of deletion, black arrows indicate PCR primers location; right, PCR genotyping across breakpoints at diagnosis and relapse, a breakpoint-specific PCR product corresponding to TRAF3 deletion was detected only at relapse indicating that this rearrangement was acquired at relapse. Bottom, sequence of the PCR product spanning the breakpoint junction of the deletion; letters in green indicate nucleotides deleted and letters in red indicate identical sequences at the site of the breakpoint. Dashed circle indicates that the frequency of this subclone is too low (o20%) to be detected. Deletion in TRAF3 removes four coding exons. D, diagnosis; R, relapse. Chr., chromosome.
Genomic Genomic analysis of relapsed multiple myeloma F Magrangeas et al cases) and TP53 deletion (two cases). Lesions present at diagnosis were lost in 10 (42%) cases at relapse (Supplementary Table 6 ). In addition, changes in the proportions of myeloma cell populations harboring subclones present at diagnosis were identified in five cases (Supplementary Table 6 ). For example, in patient #39, a minor subpopulation with a biallelic deletion targeting AJAP1 at diagnosis became predominant at relapse (Supplementary Figure 4) . These results suggest that, at least in some patients, a complex clonal evolutionary process occurs during disease progression.
Clonal relationships between matched diagnostic and relapse MM samples Unsupervised clustering analysis using SNP array data indicated a clear clonal relationship between all matched diagnostic and relapse MM samples (Figure 1 ). The pattern of deletions at immunoglobulin gene loci confirmed a common clonal origin, although rearrangement-associated deletions across all loci were highly variable between individual MM cases (Supplementary Figure 5) . These data strongly suggested that relapse represented intraclonal evolution and diversification of the myeloma cell population present at diagnosis.
Nonlinear evolution in MM patients at relapse The marked genetic heterogeneity among patients and dominating subclones at diagnosis, combined with the diversity of changes at relapse, prompted to focus the study on a limited number of recurrent secondary genetic events. In the 24 cases, seven genomic lesions were scrutinized, respectively, involving the 1q21 locus, NF-kB pathway regulators TRAF3, cIAP1/2, CYLD and CD40 as well as RB1 and TP53 tumor suppressor genes. Reporting each lesion based on SNP array analysis allowed to identify a genetic profile for each patient and establish the relative abundance of genetically distinct subclones at the respective time points of diagnosis and relapse ( Supplementary Figures 1-3) . From these comparisons, it was therefore possible to infer for each patient whether the relapse had a clonal origin, assuming that the acquisition of a genomic lesion (CNAs or CN-LOH) is irreversible and therefore drives changes unidirectionally by sequential acquisition of one or more events. Three equivalent patterns emerged from this analysis, with eight patients in each group. For a first third of the cases, there were no differences between diagnostic and relapse clones. For another third, the relapse clone apparently derived from the major subclone at diagnosis but continued to diversify through additionally acquired lesions (Figures 2a and b) , although it cannot be excluded that more than one subclone had contributed to relapse (Figure 2c ). For the final third of patients, the relapse clone clearly derived from a minor subclone, barely present at diagnosis. For example, dominant subclones at diagnosis with biallelic deletion of cIAP1/ 2 (MM patient #38; Figure 3a ) or biallelic deletion of RB1 (MM patient #41; Figure 3b ) were absent at relapse. This indicates that a preexisting minor subclone blossomed at relapse. As a consequence, in both of these cases, selection of the minor clone lacking the relevant biallelic deletion led to a large increase of either cIAP1/2-or RB1-expressing cells at relapse. In most of the patients, the relapse clone continued to diversify by acquiring one or two secondary genetic events (MM patient #11; Figure 4 ) and also invaded PB (MM patient #42; Figure 5 ). Bifurcation in clonal evolution contra-selected subclones carrying various lesions including chromosome 17 CN-LOH, chromosome 22 deletion, chromosome 2 gain, 7q11.22-q22.11 gain and 1p22.1-p13.3 deletion (see Supplementary Figure 7 ). Nonlinear patterns of evolution were also observed in two patients without changes in the secondary genetic events explored (Supplementary Figure 8) .
Of note, reordering of intraclonal architecture was mostly observed in patients treated with the proteasome inhibitor bortezomib rather than in patients treated with conventional chemotherapy (P ¼ 0.036; Supplementary Table 7) .
Upregulation of NF-kB genes at relapse Functional changes associated with the acquisition of CNAs and CN-LOH, and combined with the emergence of minor subclones at relapse. A gene set enrichment analysis was therefore performed, comparing gene expression profiles between diagnostic MM (n ¼ 11) and relapse MM (n ¼ 12). This revealed a significant difference in the expression pattern of known NF-kB pathway genes, notably enriched at relapse (gene set: ST_TUMOR_NECRO-SIS_FACTOR_PATHWAY, P ¼ 0.037, Supplementary Table 8 and Supplementary Figure 9) . Conversely, in diagnosis cases, there was an overrepresentation of downregulated genes when the NF-kB pathway is activated (gene set: BASSO_CD40_SIGNALING_DN, P ¼ 0.002, Supplementary Table 9 ). These results, together with data showing that in four patients relapse-acquired lesions targeted NF-kB regulators, strongly suggest that activation of this pathway could contribute to relapse mechanisms in MM.
DISCUSSION
In this study, genomic anomalies were screened in mature tumor cells (CD138 þ ) from MM patients. Comparison of paired diagnosis and relapse DNA samples by SNP array revealed two distinct patterns of subclonal evolution in MM in the two thirds of Figure 5 . Nonlinear subclonal evolution with new acquisition at relapse and extramedullary expansion in patient no. 42. Relapse clone originating from minor subclone at diagnosis with bifurcation, diversification and extramedullary expansion. Proportion of subclones inferred from SNP array data on diagnostic versus relapse are indicated. Top rows (dots) display the copy number (CN) defined as the mediansmoothed intensity with a window of five markers of diagnosis (blue) and relapse (red), bottom rows display allele-specific copy number (ASCN) with minimum (orange) and maximum allele (gray) intensities. (a) Deletion of chromosome 22 at diagnosis. CN between 1.5 and 1, and minimum allele intensity o0.5 detached from the maximum allele indicate two subclones: one deleted (80% of the population) and the other diploid (20%) (Supplementary Figure 1) . Normal diploid chromosome 22 at relapse; CN at 2 and ASCN shows both alleles separated with the minimum allele (orange) intensity 1 indicating that the most likely subclone that gave rise to relapse had two copies of chromosome 22. Acquisition of biallelic deletion of cIAP1/2 at relapse. CN near 0 indicates a predominant subclone with cIAP1/2 biallelic deletion and a very minor subclone with cIAP1/2 monoallelic deletion. Secondary genetic lesions with changes between diagnostic and relapse are indicated in red. (b) Genomic pattern of cIAP1/2 rearrangements acquired at relapse. Top left, genomic map showing position and log 2 ratio copy number of array probes as individual vertical line (orange for diagnosis and blue for relapse) and region of deletion, black arrows indicate PCR primers location; right, PCR genotyping across breakpoints at diagnosis and relapse, a breakpoint-specific PCR product corresponding to cIAP1/2 locus deletion was detected only at relapse indicating that this rearrangement was acquired at relapse. Bottom, sequence of the PCR product spanning the breakpoint junction of the deletion, letters in green indicate nucleotides deleted and letters in red indicate identical sequences at the site of the breakpoint. Bottom, mapping of the genes involved in the rearrangements using UCSC Genome Browser (NCBI36/hg18). Intrachromosomal rearrangements on chromosome 11q that combine a short deletion, an inversion and a large deletion remove 16 genes including cIAP1/2 (BIRC2/BIRC3). An illustration of the inverted sequence and deletions is shown on the right. Inverted sequence relative to the reference is in red; those in the same orientation are in blue and green. The black loops represent the deleted sequence. Genomic location is indicated. D, diagnosis; R, relapse; R*, blood sample collected at relapse. Chr., chromosome.
patients with new clones at relapse. A linear pattern was disclosed, in which the major diagnosis subclone acquired additional lesions and evolved to a relapse subclone. Second, a nonlinear pattern was observed in a third of the patients, in which the dominant subclone at presentation was killed by therapy while a minor subclone survived and expanded at relapse. This nonlinear pattern was observed preferentially in patients treated with bortezomib rather than those treated with conventional induction chemotherapy, and preferably in patients who achieved complete response or very good partial response. This suggests that bortezomibbased treatment specifically extinguishes the dominant subclone carrying the 'driver' mutation of symptomatic MM, while other subclones persist, providing a reservoir for relapse. Minor subclones that are not initially competitive against the dominant population cells therefore have a chance to thrive and acquire new anomalies. The apparent difference in terms of selection pressure between pathway-oriented and conventional drugs could explain why, in the IFM 2005-01 phase III trial, the better response rate observed in patients who received bortezomib plus dexamethasone versus VAD was not fully translated into a significant longer progression-free survival. 4 Intraclonal evolution diversity in the course of MM was screened here with a limited number of CNAs referred to as secondary genetic lesions, at two time points and in a small cohort of patients, with a 20% threshold for the detection of subclone frequency. For these reasons, and because of the number and variety of CNAs at diagnosis, this provided an underestimated image of the genetic evolution of MM. Moreover, mature tumor cells were selected, leaving out possible other anomalies present in earlier stages of MM maturation, such as CD138 À precursors or side population progenitors. 14, 15 Nevertheless, these data suggest a profound reorganization and diversification of the subclonal population with frequent nonlinear dynamics during disease progression. They also demonstrate that MM not only have multiple subclones at diagnosis but also retain the capacity to diversify through additional acquired lesions, especially in nonlinear pattern. This was particularly well illustrated with patient no. 41 and no. 42. In the latter case, the subclonal bifurcation involved at least three lesions harbored by the major subclone(s) at diagnosis. Moreover, diversification/evolution was attested by the acquisition of more than 10 new lesions at relapse, including homozygous deletions targeting FAT3, MTNR1B, cIAP1/2 and SLITRK1, strongly suggesting increased genomic instability during progression. This feature was reinforced by the breakpoint signature observed at the cIAP1/2 locus in patient no. 42, characterized by the presence of microhomology at junctions, with deletions of various lengths and inverted sequences. This is consistent with microhomology-mediated break-induced replication complex rearrangements described to be compatible with genomic instability [16] [17] [18] This study moreover confirmed the central role of constitutive NF-kB activation in the progression of MM and relapse. 19, 20 This phenomenon is probably complex and may result from the combination of newly acquired activating mutations, cooperation with other pathways and/or changes in the microenvironment. However, the strong evolutionary plasticity of subclones harboring biallelic deletion of cIAP1/2 (BIRC2/3) with either re-emergence, eradication or emergence of subclones described in this work and recently by Keats et al. 21 indicates that clonal dynamics also contributes to deregulation of the NF-kB pathway in myeloma patients at relapse.
While single-cell whole-genome sequencing will be ultimately required to define precisely the frequency of subclonal populations and the mutations in the founding clone evolution, these data together with those prepublished online [21] [22] [23] extend results obtained in other hematological malignancies. [24] [25] [26] [27] Together with previous results showing subclonal heterogeneity at several stages of the disease, [28] [29] [30] [31] these data support the concept of a Darwinian model of clonal evolution in cancer, 6 in the context of MM progression and relapse. 32 This conceptual framework has clinical implications in MM as treatment clearly appeared to affect clonal selection. In a Darwinian model of clonal evolution, the sequence of treatment (induction, consolidation and maintenance) using drugs with various modes of action, such as alkylating agents, immunomodulators and proteasome inhibitors, is therefore a crucial point to consider in order to eradicate the more aggressive subclones and control indolent subpopulations in order to obtain long-term remission. In the near future, with the advent of targeted drugs, in addition to risk stratification (based on interphase fluorescent in situ hybridization, gene expression profiling or SNP array, 33 the identification of altered pathways and allelic variant frequency at presentation could be critical to combine and sequence the usage of different drugs.
